These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 20232355)

  • 1. Antagonists of growth hormone-releasing hormone inhibit the proliferation of human benign prostatic hyperplasia cells.
    Siejka A; Schally AV; Block NL; Barabutis N
    Prostate; 2010 Jul; 70(10):1087-93. PubMed ID: 20232355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia.
    Rick FG; Schally AV; Block NL; Nadji M; Szepeshazi K; Zarandi M; Vidaurre I; Perez R; Halmos G; Szalontay L
    Proc Natl Acad Sci U S A; 2011 Mar; 108(9):3755-60. PubMed ID: 21321192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia.
    Rick FG; Schally AV; Block NL; Abi-Chaker A; Krishan A; Szalontay L
    Prostate; 2013 Jun; 73(8):873-83. PubMed ID: 23280565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers.
    Klukovits A; Schally AV; Szalontay L; Vidaurre I; Papadia A; Zarandi M; Varga JL; Block NL; Halmos G
    Cancer; 2012 Feb; 118(3):670-80. PubMed ID: 21751186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of a novel antagonist of growth hormone releasing hormone on cell proliferation and on the key cell signaling pathways in nine different breast cancer cell lines.
    Pozsgai E; Schally AV; Hocsak E; Zarandi M; Rick F; Bellyei S
    Int J Oncol; 2011 Oct; 39(4):1025-32. PubMed ID: 21701777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth hormone-releasing hormone antagonists reduce prostatic enlargement and inflammation in carrageenan-induced chronic prostatitis.
    Popovics P; Cai R; Sha W; Rick FG; Schally AV
    Prostate; 2018 Sep; 78(13):970-980. PubMed ID: 29786867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of acute and chronic administration of a new potent antagonist of growth hormone-releasing hormone in rats: mechanisms of action.
    Kovacs M; Zarándi M; Halmos G; Groot K; Schally AV
    Endocrinology; 1996 Dec; 137(12):5364-9. PubMed ID: 8940358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of antagonists of growth hormone-releasing hormone (GHRH) on GH and insulin-like growth factor I levels in transgenic mice overexpressing the human GHRH gene, an animal model of acromegaly.
    Kovacs M; Kineman RD; Schally AV; Zarandi M; Groot K; Frohman LA
    Endocrinology; 1997 Nov; 138(11):4536-42. PubMed ID: 9348175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antagonists of growth hormone-releasing hormone inhibit proliferation induced by inflammation in prostatic epithelial cells.
    Popovics P; Schally AV; Salgueiro L; Kovacs K; Rick FG
    Proc Natl Acad Sci U S A; 2017 Feb; 114(6):1359-1364. PubMed ID: 28123062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer.
    Muñoz-Moreno L; Arenas MI; Schally AV; Fernández-Martínez AB; Zarka E; González-Santander M; Carmena MJ; Vacas E; Prieto JC; Bajo AM
    Int J Cancer; 2013 Feb; 132(4):755-65. PubMed ID: 22777643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage.
    Rick FG; Szalontay L; Schally AV; Block NL; Nadji M; Szepeshazi K; Vidaurre I; Zarandi M; Kovacs M; Rekasi Z
    J Urol; 2012 Apr; 187(4):1498-504. PubMed ID: 22341819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Essential role of p21/waf1 in the mediation of the anti-proliferative effects of GHRH antagonist JMR-132.
    Volakaki AA; Lafkas D; Kassi E; Schally AV; Papavassiliou AG; Kiaris H
    J Mol Endocrinol; 2008 Nov; 41(5):389-92. PubMed ID: 18765563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of GHRH antagonists on human glioblastomas and their mechanism of action.
    Pozsgai E; Schally AV; Zarandi M; Varga JL; Vidaurre I; Bellyei S
    Int J Cancer; 2010 Nov; 127(10):2313-22. PubMed ID: 20162575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of estrogen receptor positive and negative breast cancer cell lines with a growth hormone-releasing hormone antagonist.
    Seitz S; Hohla F; Schally AV; Moder A; Engel JB; Horn F; Varga J; Zarandi M; Ortmann O; Köster F; Buchholz S
    Oncol Rep; 2008 Nov; 20(5):1289-94. PubMed ID: 18949435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function.
    Szalontay L; Schally AV; Popovics P; Vidaurre I; Krishan A; Zarandi M; Cai RZ; Klukovits A; Block NL; Rick FG
    Cell Cycle; 2014; 13(17):2790-7. PubMed ID: 25486366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effects of GHRH antagonists on human GH-secreting adenoma tissue.
    Szalontay L; Benveniste RJ; Schally AV; Vidaurre I; Nadji M; Zarandi M; Block NL; Kovacs M
    Neuroendocrinology; 2012; 96(1):81-8. PubMed ID: 22377963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer.
    Papadia A; Schally AV; Halmos G; Varga JL; Seitz S; Buchholz S; Rick F; Zarandi M; Bellyei S; Treszl A; Szalontay L; Lucci JA
    Horm Metab Res; 2011 Oct; 43(11):816-20. PubMed ID: 22009378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular mechanisms of growth inhibition of human endometrial cancer cell line by an antagonist of growth hormone-releasing hormone.
    Zhao L; Yano T; Osuga Y; Nakagawa S; Oishi H; Wada-Hiraike O; Tang X; Yano N; Kugu K; Schally AV; Taketani Y
    Int J Oncol; 2008 Mar; 32(3):593-601. PubMed ID: 18292936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
    Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
    Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases.
    Rick FG; Schally AV; Szalontay L; Block NL; Szepeshazi K; Nadji M; Zarandi M; Hohla F; Buchholz S; Seitz S
    Proc Natl Acad Sci U S A; 2012 Jan; 109(5):1655-60. PubMed ID: 22307626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.